The truce covers tariffs as Washington turns to capital and components

The noise is in the truce, the signal in capital

The headlines are about the tariff truce between the US and China, now extended to January, and about Trump attending the Shenzhen APEC summit on 18–19 November. At first glance that suggests a cooling on the technology front. Yet on 22 October, 27 days before the summit, Washington rolled out two new tools from two separate agencies, and both operate outside the tariff talks.

The Treasury published a draft rule implementing the COINS Act, passed in December 2025 as part of the defence authorisation bill for fiscal 2026. Using the Secretary's discretion, the draft adds biotech to semiconductors, AI, quantum, high-performance computing and hypersonics; the Treasury's statement puts the number of areas at 6. On the same day the FCC blocked 2 devices carrying a chip from HiSilicon, a Huawei subsidiary. It was the first case under the component rule that took effect on 13 October. One tool targets capital flowing to China; the other targets Chinese components entering the US.

Why biotech is on the list now

The draft defines biotech broadly. According to a Treasury fact sheet cited by BioPharm International, it covers biologically derived compounds, brain-computer interfaces, biomanufacturing equipment, sequencing and biological design technologies, and bioinformatics tools. Equity acquisitions, convertible debt, joint ventures, greenfield investment and some fund investments fall under review. The countries of concern are China, including Hong Kong and Macau, Cuba, Iran, North Korea and Russia.

The critical detail lies in the exemption. Pure licensing deals, meaning transfers of drug rights for upfront payments, milestones and royalties, are excluded. Structures that involve a transfer of technology or know-how do not qualify. According to AP, the rule will apply to investments above 50,000 dollars, and many financial investments, such as buying listed shares, will remain outside it. STAT wrote that the draft is tougher than expected but could change during the comment period. MassBio, which has more than 1,700 members in Massachusetts, said it would submit comments.

Beijing's move mirrors the same exemption. According to Bloomberg, China proposed a week earlier to add several biomedical technologies to its own export control list, while explicitly allowing drug licensing deals to continue. Both capitals are narrowing flows of capital and technology to each other's companies while keeping molecule licensing open. Chinese foreign ministry spokeswoman Mao Ning said the concept of national security was being overstretched and that Beijing would take the necessary measures.

The component rule scans the supply chain from inside

The FCC's step is narrower but structurally deeper. According to The Record, until 13 October a device made by another company could win approval even if it contained a part from a firm on the Covered List. The new rule bars approval of devices that contain logic-bearing components from companies on the list, which has been kept since 2019. The makers of the vehicle camera and wireless video transmitter blocked on 22 October were not named.

Enforcement has moved from the brand level down to the chip level. FCC chairman Brendan Carr said the agency would keep enforcing the rule aggressively. For third-party camera and IoT makers in Asia, the result is the cost of component declarations and supplier changes to secure US approval. The 200,000-dollar penalty the Treasury imposed in July over an unreported 92,500-dollar investment also shows that compliance failures are expensive.

What would falsify this reading

Our thesis is that Washington is preserving the tariff truce while pursuing technology competition through capital and components, and that these channels will stay outside the APEC bargaining. We put the probability of the rule being finalised with narrower drug provisions at 55%. A wider scope met by Beijing's retaliation stands at 30%, and a suspension of both steps at APEC at 15%.

The first falsifier: if a joint statement after 18–19 November says investment restrictions are postponed, the capital channel will have entered the bargaining. The second: if the final version of China's biomedical export control list removes the licensing exemption, the door both sides kept open would close and our stability assumption would collapse. The third: if the FCC announces no new component case before the end of 2026, the rule will remain symbolic.